Atossa Genetics (NASDAQ:ATOS) & Treace Medical Concepts (NASDAQ:TMCI) Critical Analysis

Treace Medical Concepts (NASDAQ:TMCI) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Treace Medical Concepts and Atossa Genetics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treace Medical Concepts	2	4	1	0	1.86
Atossa Genetics	2	0	3	0	2.20

Treace Medical Concepts presently has a consensus price target of $4.97, suggesting a potential upside of 17.49%. Atossa Genetics has a consensus price target of $20.33, suggesting a potential upside of 716.60%. Given Atossa Genetics’ stronger consensus rating and higher possible upside, analysts plainly believe Atossa Genetics is more favorable than Treace Medical Concepts.

Profitability

This table compares Treace Medical Concepts and Atossa Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Treace Medical Concepts	-29.44%	-67.04%	-30.28%
Atossa Genetics	N/A	-84.91%	-72.36%

Institutional and Insider Ownership

84.1% of Treace Medical Concepts shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 23.4% of Treace Medical Concepts shares are owned by insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Treace Medical Concepts and Atossa Genetics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treace Medical Concepts	$212.69 million	1.29	-$59.00 million	($0.97)	-4.36
Atossa Genetics	N/A	N/A	-$34.77 million	($3.21)	-0.78

Atossa Genetics has lower revenue, but higher earnings than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Treace Medical Concepts has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, Atossa Genetics has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.

Summary

Treace Medical Concepts beats Atossa Genetics on 7 of the 13 factors compared between the two stocks.

About Treace Medical Concepts

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

About Atossa Genetics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.